FindTrial
Sign In

Analysis of clinical,histopathological and immunological features of bullous pemphigoid induced by dipeptidyl peptidase -4 inhibitors

Characterization of the clinical,histopathological and immunological features of dipeptidylpeptidase -4 inhibitor induced bullous pemphigoid

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/08/027157
Enrollment
40
Registered
2020-08-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L120- Bullous pemphigoid

Interventions

None listed

Sponsors

Indian association of DermatologistsVenereologists and Leprologists
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Recent-onset vesicobullous skin lesions clinically suggestive of bullous pemphigoid 2. Aged 18 years and above

Exclusion criteria

Exclusion criteria: 1)Patients not willing to give consent 2.Patients not willing to follow up for 6 months

Design outcomes

Primary

MeasureTime frame
1)Bullous Pemphigoid Disease Activity Index (BPDAI) shall be calculated at baseline in all patients, including the total BPDAI activity score and the total BPDAI damage score 2)histopathological and Direct immunofluorescence patterns: 3) Expression of DPP-4, DPP-8, DPP-9 and Caspase-1 by immunohistochemistry (IHC) in the biopsy specimens shall also be determined in all subjects. 4)time taken to remission 5.)ELISA for anti- BP180 and BP 230 antibodies shall be done to detect antibodies Timepoint: 1)Bullous Pemphigoid Disease Activity Index (BPDAI) shall be calculated at baseline and monthly 2)Histopathological and Direct immunofluorescence patterns, Expression of DPP-4, DPP-8, DPP-9 and Caspase-1 by immunohistochemistry (IHC) ELISA for anti- BP180 and BP 230 antibodies shall be done at baseline and at 6 months or at time of remission (whichever is earlier)—

Secondary

MeasureTime frame
To ascertain the prevalence of dipeptidyl peptidase-4 inhibitor-induced bullous pemphigoid among cases of bullous pemphigoid 2. To compare the characteristics of dipeptidyl peptidase-4 inhibitor-induced bullous pemphigoid with those of non-gliptin induced bullous pemphigoid Timepoint: Monthly for 6 months or at remission whichever is earlier—

Countries

India

Contacts

Public ContactDr Sanjeev Handa

Post Graduate Institute of Medical Education and Research, Chandigarh

handa_sanjeev@yahoo.com9815924777

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026